Inhaled Formoterol Diminishes Insulin-Induced Hypoglycemia in Type 1 Diabetes | Zendy

Renata BelfortDeAguiar | Zendy; Sarita Naik | Zendy; Janice J. Hwang | Zendy; Barbara Szepietowska | Zendy; Robert S. Sherwin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Inhaled Formoterol Diminishes Insulin-Induced Hypoglycemia in Type 1 Diabetes

Author(s) -

Renata BelfortDeAguiar,

Sarita Naik,

Janice J. Hwang,

Barbara Szepietowska,

Robert S. Sherwin

Publication year - 2015

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc14-2472

Subject(s) - medicine , hypoglycemia , diabetes mellitus , formoterol , insulin , type 1 diabetes , type 2 diabetes , endocrinology , asthma , budesonide

Hypoglycemia is one of the major factors limiting implementation of tight glycemic control in patients with type 1 diabetes and is associated with increased morbidity and mortality during intensive insulin treatment. β-2 Adrenergic receptor (AR) agonists have been reported to diminish nocturnal hypoglycemia; however, whether long-acting inhaled β-2 AR agonists could potentially be used to treat or prevent hypoglycemia has not been established.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research